DÄ internationalArchive37/2007Current Treatment of Parkinson´s Disease

cme

Current Treatment of Parkinson´s Disease

Dtsch Arztebl 2007; 104(37): A-2513

Wojtecki, L; Südmeyer, M; Schnitzler, A

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. de Rijk MC, Launer LJ, Berger K et al.: Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: 21–3. MEDLINE
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4. MEDLINE
3. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33–9. MEDLINE
4. Oertel WH et al.: Parkinson-Syndrome. In: Diener HC, ed.: Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag, 2005; 48–72.
5. Hoehn MM: The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10: 331–9. MEDLINE
6. Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297–305. MEDLINE
7. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama 2000; 284: 1931–8. MEDLINE
8. Rinne UK, Bracco F, Chouza C et al.: Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48: 363–8. MEDLINE
9. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91. MEDLINE
10. The Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721–8. MEDLINE
11. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB: Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078–82. MEDLINE
12. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29–38. MEDLINE
13. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39–46. MEDLINE
14. Kurth MC, Adler CH, Hilaire MS et al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81–7. MEDLINE
15. Rinne UK, Larsen JP, Siden A, Worm-Petersen J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51: 1309–14. MEDLINE
16. Henchcliffe C, Schumacher HC, Burgut FT: Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 2005; 5: 811–21. MEDLINE
17. Rascol O, Brooks DJ, Melamed E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947–54. MEDLINE
18. Crosby NJ, Deane KH, Clarke CE: Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003(2): CD003467. MEDLINE
19. Crosby N, Deane KH, Clarke CE: Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003(1): CD003468. MEDLINE
20. Schwab RS, Amador LV, Lettvin JY: Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951; 56: 251–3. MEDLINE
21. Poewe W, Wenning GK: Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000; 15: 789–94. MEDLINE
22. Deep-Brain Stimulation for Parkinson´s Disease Study Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345: 956–63.
23. Deuschl G, Schade-Brittinger C, Krack P et al.: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908. MEDLINE
24. Emre M, Aarsland D, Albanese A et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18. MEDLINE
25. The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63. MEDLINE

Info

Specialities